5-ALA

DRUG5 trials

Sponsors

Yamaguchi University, University College, London, St. Joseph's Hospital and Medical Center, Phoenix, Fox Chase Cancer Center, University of Colorado, Denver

Conditions

GlioblastomaGliomaSoft Tissue Sarcoma (STS)Solid Tumormilignant glioma

Early Phase 1

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma

Not yet recruitingNCT07038278

University of Colorado, DenverSoft Tissue Sarcoma (STS)

Start: 2026-09-01End: 2028-11-01Target: 20Updated: 2026-07-22

Phase 1

Phase I Study in Advanced Malignancies With 5-ALA

SuspendedNCT04381806

Fox Chase Cancer CenterSolid Tumor

Start: 2020-07-30End: 2028-02-01Target: 130Updated: 2026-05-22

Phase 2

Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma

CompletedNCT01310868

University College, LondonGlioblastoma

Start: 2011-05-31End: 2015-03-31Updated: 2017-10-05

Unknown Phase

photodynamic diagnosis with 5-aminolevulinic acid

Active, not recruitingJPRN-UMIN000008706

Yamaguchi Universitymilignant glioma

Start: 2012-04-01Target: 50Updated: 2026-06-29

5-ALA in Recurrent Glioma

St. Joseph's Hospital and Medical Center, PhoenixGlioma

Start: 2014-02-28End: 2017-09-30Target: 60Updated: 2017-01-06